Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ES009 |
Synonyms | |
Therapy Description |
ES009 is a monoclonal antibody that targets LILRB2 (ILT4), which may promote a pro-inflammatory state and increase anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ES009 | ES 009|ES-009 | ES009 is a monoclonal antibody that targets LILRB2 (ILT4), which may promote a pro-inflammatory state and increase anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06007482 | Phase I | ES009 | A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |